Stock Performance Spotlight: Arcutis Biotherapeutics Inc (ARQT) Ends the Day at 8.49, Up by 2.54

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $8.49, up 2.54% from its previous closing price of $8.28. In other words, the price has increased by $2.54 from its previous closing price. On the day, 8.09 million shares were traded. ARQT stock price reached its highest trading level at $8.66 during the session, while it also had its lowest trading level at $8.21.

Ratios:

To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.61 and its Current Ratio is at 9.89. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.92.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.

On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.

Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 04 ’24 when Welgus Howard G. sold 10,000 shares for $8.01 per share. The transaction valued at 80,092 led to the insider holds 170,200 shares of the business.

Burnett Patrick sold 23,000 shares of ARQT for $201,319 on May 30 ’24. The insider now owns 209,793 shares after completing the transaction at $8.75 per share. On May 29 ’24, another insider, Burnett Patrick, who serves as the insider of the company, sold 49,952 shares for $8.72 each. As a result, the insider received 435,387 and left with 209,793 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 982836352 and an Enterprise Value of 785711744. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.24 while its Price-to-Book (P/B) ratio in mrq is 4.36. Its current Enterprise Value per Revenue stands at 7.385 whereas that against EBITDA is -4.03.

Stock Price History:

Over the past 52 weeks, ARQT has reached a high of $13.17, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -3.29%, while the 200-Day Moving Average is calculated to be 33.99%.

Shares Statistics:

It appears that ARQT traded 2.94M shares on average per day over the past three months and 2998920 shares per day over the past ten days. A total of 115.76M shares are outstanding, with a floating share count of 99.22M. Insiders hold about 14.29% of the company’s shares, while institutions hold 98.52% stake in the company. Shares short for ARQT as of 1715731200 were 22173654 with a Short Ratio of 8.39, compared to 1713139200 on 19662102. Therefore, it implies a Short% of Shares Outstanding of 22173654 and a Short% of Float of 23.76.

Most Popular